Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Diabetologia 60, 215225
GkeBGallwitzBErikssonJGHellqvistGause-NilssonI
Key distinctions in the evidence: Tesamorelin: licensed in the US, narrowly indicated, established in HIV-related lipodystrophy, with effects that reverse on stopping treatment Retatrutide: investigational, broader metabolic potential, not yet approved anywhere globally Patients and clinicians should interpret early-phase data for retatrutide with appropriate caution
Patients should track mood changes, especially during weeks 14 of treatment
US$ 28.75
US$ 22.04
US$ 21.76
US$ 29.44
US$ 29.29
US$ 28.25
US$ 23.64
US$ 21.46
